Symbicort® (budesonide/formoterol) Asthma

This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Asthma ICS/LABAs and Symbicort®

Exacerbation reduction

Symbicort® SMART reduced the incidence of severe asthma exacerbations** by 39% vs salmeterol/fluticasone + SABA7

Symbicort® SMART* prolonged the time to first severe exacerbation**(primary variable) vs fixed-dose salmeterol/fluticasone and Symbicort® (33% reduction in hazard ratio p=0.003 and 26% reduction in hazard ratio p=0.026, respectively).7

There were no differences between treatments in terms of mild exacerbations, lung function, asthma control days*** and asthma-related quality of life. Another secondary endpoint showed fewer severe exacerbations** with Symbicort® SMART* 200/6 μg bd + additional inhalations as needed vs salmeterol/fluticasone 50/250 μg bd + SABA as needed.7

Rate of severe exacerbation** events per 100 patients every 6 months was 19 for salmeterol/fluticasone + SABA and 12 for Symbicort® SMART* (p<0.001). The total number of severe exacerbations** was 208 and 125 for salmeterol/fluticasone + SABA and Symbicort® SMART*, respectively.7